<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">Recently, Murrell et al
 <xref rid="bib56" ref-type="bibr">
  <sup>56</sup>
 </xref> reviewed data from pivotal clinical trials in psoriasis and found that URIs were increased with TNF inhibitors compared with placebo but that URI rates were comparable between placebo and IL-17, IL-12/23, and IL-23 inhibitors. A different group also reviewed the clinical trial data for all 11 biologic therapies approved in psoriasis and found no significant increase in URI or influenza infection rates compared with placebo.
 <xref rid="bib57" ref-type="bibr">
  <sup>57</sup>
 </xref> In contrast, Wan et al
 <xref rid="bib58" ref-type="bibr">
  <sup>58</sup>
 </xref> recently published a meta-estimate of pivotal clinical trials with 3 IL-17 inhibitors and found an increased risk of viral and nonviral URIs compared with placebo (odds ratio [OR], 1.56; 95% CI, 1.04-2.33).
</p>
